RECURSION PHARMACEUTICALS, INC. Insider Trading Arrangements
Rule 10b5-1 and other trading arrangements that directors and officers adopted or terminated, as each 10-Q and 10-K tags them (Item 408(a)), newest report first.
- 2026-05-06: Individual Namandjé Bumpus; Title a member of our Board of Directors; Arrangement Rule 10b5-1; Adopted March 3, 2026.
- 2026-02-25: Individual Robert Hershberg; Title Vice Chair and Lead Independent Director; Arrangement Rule 10b5-1; Adopted December 18, 2025.
- 2025-11-05: Individual Blake Borgeson; Title a member of our Board of Directors; Arrangement Rule 10b5-1; Adopted August 31, 2025.
- 2025-11-05: Individual Najat Khan; Title Chief R&D Officer, Chief Commercial Officer, and a member of our Board of Directors; Arrangement Rule 10b5-1; Adopted September 22, 2025.
| Report filed | Individual | Title | Arrangement | Adopted | Terminated | Expires or duration | Securities covered |
|---|---|---|---|---|---|---|---|
| 2026-05-06 10-Q | Namandjé Bumpus | a member of our Board of Directors | Rule 10b5-1 | March 3, 2026 | June 2, 2027 P456D | 12,735 | |
| 2026-02-25 10-K | Robert Hershberg | Vice Chair and Lead Independent Director | Rule 10b5-1 | December 18, 2025 | March 19, 2027 P456D | 525,000 | |
| 2025-11-05 10-Q | Blake Borgeson | a member of our Board of Directors | Rule 10b5-1 | August 31, 2025 | P457D | 3,868,000 | |
| 2025-11-05 10-Q | Najat Khan | Chief R&D Officer, Chief Commercial Officer, and a member of our Board of Directors | Rule 10b5-1 | September 22, 2025 | December 22, 2026 P456D | 299,317 | |
| 2025-11-05 10-Q | Ben Taylor | Chief Financial Officer and President of Recursion UK | Rule 10b5-1 | September 30, 2025 | December 29, 2026 P455D | 293,321 | |
| 2025-08-05 10-Q | Christopher Gibson | CEO and President | Rule 10b5-1 | May 12, 2025 | August 13, 2026 P458D | ||
| 2025-08-05 10-Q | |||||||
| 2025-08-05 10-Q | Christopher Gibson | CEO and President | Rule 10b5-1 | May 12, 2025 | |||
| 2025-08-05 10-Q | 86,634 | ||||||
| 2025-08-05 10-Q | 4,247,433 | ||||||
| 2025-02-28 10-K | Christopher Gibson | Chief Executive Officer, President, and a member of our Board of Directors | Rule 10b5-1 | December 19, 2024 | April 9, 2026 P476D | 2,343,000 | |
| 2024-05-09 10-Q | Terry-Ann Burrell | member of our Board of Directors | Rule 10b5-1 | March 1, 2024 | P455D | 211,290 | |
| 2024-05-09 10-Q | Tina Marriott | President and Chief Operating Officer | Rule 10b5-1 | March 1, 2024 | P483D | 672,000 | |
| 2024-05-09 10-Q | Michael Secora | Chief Financial Officer | Rule 10b5-1 | March 1, 2024 | P466D | 1,259,955 | |
| 2024-02-29 10-K | Christopher Gibson | Chief Executive Officer and a member of our Board of Directors | Rule 10b5-1 | December 27, 2023 | P435D | 620,015 | |
| 2023-11-09 10-Q | Blake Borgeson | member of our Board of Directors | Rule 10b5-1 | August 18, 2023 | P452D | 745,186 | |
| 2023-11-09 10-Q | Dean Li, | member of the Board of Directors | Rule 10b5-1 | August 24, 2023 | P454D | 155,500 | |
| 2023-08-08 10-Q | Zavain Dar | member of our Board of Directors | Rule 10b5-1 | June 21, 2023 | P366D | 20,141 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |